相关实验视频
Updated: Sep 16, 2025

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
22.0K
对于中风的静脉血栓溶解后的早期蒂罗菲班输液
Chunrong Tao1, Tianlong Liu1, Tao Cui2
1Department of Neurology, First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
The New England journal of medicine
|July 5, 2025
概括
在接受血栓溶解的急性缺血性中风患者中,早期的蒂罗菲班治疗改善了功能结果. 这项研究发现,使用蒂罗菲班的患者有更高的良好的康复可能性,尽管出血风险略有增加.
科学领域:
- 神经学 神经学
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 内静脉血栓溶解是一种标准的急性缺血性中风治疗方法.
- 血栓溶解后的血管再封闭是一个令人担忧的问题.
- 作为一种糖蛋白IIb-IIIa抑制剂的tirofiban在防止再封闭方面显示出有前途.
研究的目的:
- 评估提前在急性缺血性中风患者中提前给予蒂罗菲班的疗效和安全性.
- 为了确定皮洛菲班是否能改善血栓溶解后的功能结果.
主要方法:
- 第三阶段,多中心,双盲,随机,安慰剂对照试验.
- 414名患者接受了蒂罗菲班,418人接受了安慰剂静脉注射在血栓溶解后60分钟内.
- 主要结局:在90天后,功能结局优异 (修改的兰金尺度0-1).
主要成果:
- 泰罗菲班组中患者的比例更高,实现了优异的功能结果 (65.9%与54.9%相比).
- 症状性内出血发生在1.7%的铁奥菲班接受者中,而安慰剂组为0%.
- 90天死亡率在各组之间是相似的 (4.1%对3.8%).
结论:
- 提早的提罗非班的使用增加了在经过血栓溶解的急性缺血性中风患者的优良功能结果的可能性.
- 虽然内出血的发病率较低,但在铁奥菲班组中更高.
- 蒂罗菲班是一种潜在的辅助疗法,可以改善中风恢复.
相关概念视频
Venous Thrombosis III: Interprofessional Care
26
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
26
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
46
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
46
Anticoagulant Drugs: Low-Molecular-Weight Heparins
919
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
919
Clot Retraction and Fibrinolysis
6.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K
Acute Coronary Syndrome IV: Interprofessional Care
32
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
32
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K

